ISCHEMIA Trial: Key Questions and Answers

Area of Science:

• Cardiology
• Clinical Trials
• Cardiovascular Medicine

Background:

• Ischaemic heart disease (IHD) management involves lifestyle, medical therapy, and revascularisation.
• Revascularisation's role in stable IHD with moderate to severe ischaemia remains debated.
• The ISCHEMIA trial addressed the optimal treatment strategy for these patients.

Purpose of the Study:

• To compare an early invasive strategy (revascularisation + optimal medical therapy) versus an initial conservative strategy (optimal medical therapy alone) in stable IHD patients.
• To evaluate the impact of these strategies on major clinical outcomes and angina symptoms.
• To provide evidence for decision-making in treating stable chronic IHD.

Main Methods:

• The ISCHEMIA trial enrolled over 5,000 patients with stable coronary artery disease and moderate to severe myocardial ischaemia.
• It compared an early invasive approach with optimal medical therapy against optimal medical therapy alone, reserving revascularisation for refractory symptoms.
• Follow-up was conducted over 3.2 years.

Main Results:

• No significant differences were observed in all-cause mortality, cardiovascular death, myocardial infarction, heart failure, or stroke between the two groups.
• Patients undergoing early revascularisation reported better angina control, particularly those with severe symptomatic angina.
• The findings suggest revascularisation does not improve major adverse clinical outcomes in this population but can alleviate symptoms.

Conclusions:

• For stable ischaemic heart disease with moderate to severe ischaemia, an early invasive strategy does not confer additional benefits regarding major clinical outcomes compared to optimal medical therapy alone.
• Optimal medical therapy is crucial for all patients, with revascularisation indicated for symptom management in severe cases.
• The ISCHEMIA trial provides valuable insights into the management of stable chronic IHD, guiding clinical practice and future research.